Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A New PARP-oriented Strategy for Treating Cellular Injury

This article was originally published in Start Up

Executive Summary

PARP inhibition's been hot, especially as it relates to cancer therapy: witness the Genentech-Inotek deal in September 2006. Now researchers at Johns Hopkins have described a new mechanism triggered by PARP activation that causes cell death following reperfusion injury--information that could provider drug developers with a new set of targets for treating a host of conditions.
Advertisement

Related Content

Genentech and Inotek Pair Up in PARP Inhibition
Genentech and Inotek Pair Up in PARP Inhibition

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC091198

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel